Clinical Trial Update: Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating surufatinib plus sintilimab in metastatic neuroendocrine tumors and pancreatic carcinoma after failure of standard chemotherapy; status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumor
• Pancreatic Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma | Phase 2 | Status: UNKNOWN